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Introduction: Although most smokers diagnosed with lung can-
cer report that they want to quit smoking, many do not succeed.
Smokers who quit when lung cancer is diagnosed have improved
treatment efficacy, quality of life, and survival. Effective smok-
ing cessation interventions targeted to thoracic oncology patients
are needed.
Methods: This pilot study examined the feasibility and potential
efficacy of a 12-week program that combined smoking cessation
counseling with varenicline. Seven-day point prevalence tobacco
abstinence rates at the end of treatment were compared with a usual
care control group. From January 2008 to August 2009, patients
with a diagnosed or suspected thoracic malignancy were recruited at
their initial visit to a thoracic surgeon or thoracic oncologist at
Massachusetts General Hospital.
Results: Of 1130 patients screened, 187 (17%) were current smok-
ers, and an additional 66 (6%) reported quitting within the past 6
months. One hundred sixteen (67%) of smokers were eligible, and
49 (42%) of eligible smokers enrolled (control group n  17,
intervention group n  32). Intervention participants completed a
median of nine counseling sessions; 50% of intervention participants
completed the full varenicline course. At 12-week follow-up, bio-
chemically validated 7-day point prevalence tobacco abstinence
rates were 34.4% in the intervention group versus 14.3% in the
control group (odds ratio  3.14, 95% confidence interval 
0.59–16.62, p  0.18).
Conclusion: Our findings support the feasibility and acceptability of
this program. At the end of treatment, quit rates were higher in the
control group. Further testing is indicated to establish the efficacy of
this treatment package in a randomized clinical trial.
Key Words: Lung cancer, Smoking, Cessation, Pharmacotherapy,
Counseling.
(J Thorac Oncol. 2011;6: 1059–1065)
Cigarette smoking is the major cause of lung cancer, andmore than 219,000 new cases of lung cancer are diag-
nosed each year in the United States.1 Approximately 20 to
30% of lung cancer patients are smokers at diagnosis.2,3 The
majority of patients who receive a lung cancer diagnosis
report that they want to quit smoking, but many are unable to
do so.4–6 This is unfortunate as quitting at the time of
diagnosis can improve quality of life, improve chances for
treatment efficacy, reduce treatment complications, reduce
risk of recurrence and secondary tumors, and increase
chances of long-term survival.2,7–13
There has never been an randomized clinical trial (RCT)
for smoking cessation targeted to lung cancer patients; there
have been few randomized controlled smoking cessation trials
for cancer patients in general, and these trials have not demon-
strated a significant intervention effect.14 This lack of demon-
strated effectiveness in tobacco treatment trials for cancer pa-
tients could be due to several factors, including low power to
detect differences due to small sample sizes, lack of integration
into the cancer treatment setting, and delayed smoking cessation
treatment initiation.15–19 Another potential explanation for the
lack of success of smoking cessation programs for cancer pa-
tients is that most programs tested did not combine behavioral
and pharmacologic treatment strategies, as the United States
Public Health Service (USPHS) Treating Tobacco Use and
Dependence Clinical Practice Guideline recommends.20,21
Varenicline, a partial agonist of the alpha-4 beta-2 nico-
tinic acetylcholine receptor, received Food and Drug Adminis-
tration approval in 2006 as a smoking cessation aid and was
recommended in the 2008 USPHS guideline as a first-line
pharmacologic treatment option.22 The efficacy of varenicline
for smoking cessation in cancer patients has not been reported.
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The objective of our study was to assess the feasi-
bility and potential efficacy of a smoking cessation treat-
ment program that combined behavioral counseling with
varenicline and was targeted to patients upon their entry
into thoracic clinics.
PATIENTS AND METHODS
This study was approved by the Massachusetts General
Hospital Institutional Review Board.
Study Design and Patient Recruitment
This study used a nonrandomized design, which began
with a usual care control group enrollment period that was
followed by an intervention group enrollment period. We re-
cruited control group participants (January 2008 to June 2008)
and intervention group participants (June 2008 to August 2009)
from patients referred to thoracic surgery and oncology clinics at
the Massachusetts General Hospital (MGH) in Boston, MA.
Eligibility
Inclusion criteria for both groups were the following:
(1) suspected diagnosis of thoracic cancer; (2) smoked a
cigarette in the past 2 weeks; (3) spoke English; (4) no
metastatic disease at initial presentation; and (5) considered
medically eligible by their surgeon or oncologist. In addition,
a patient had to be willing to take varenicline to be eligible for
the intervention group; if a patient who was otherwise eligible
for the intervention group was taking nicotine replacement
therapy or bupropion, he/she had to be willing to switch to
varenicline. Patients with severe psychiatric illness as docu-
mented in the medical record (e.g., severe major depressive
disorder and active psychosis) were cleared by their psychi-
atrist or primary care physician before participating in the
study. We excluded patients known to have metastatic tho-
racic cancer before enrollment; although quitting smoking
can improve physical symptoms such as ease of breathing in
these patients, we felt that they would require a different
focus for a smoking cessation intervention.
Enrollment and Assessment Procedures
Smoking status of patients seen in participating clinics
was identified by chart review and a clinic intake form.
Eligible patients provided written informed consent and com-
pleted a baseline assessment. Two and 12 weeks after enroll-
ment, participants completed a follow-up survey. Smoking
status of reported nonsmokers was biochemically confirmed
by obtaining a saliva sample to test for cotinine, a nicotine
metabolite. Participants who were taking nicotine replace-
ment therapy at the time of an assessment provided an
expired air carbon monoxide sample. Participants were paid
$20 for completing each of the assessments.
Intervention
Intervention participants were provided with a 12-week
program consisting of varenicline (1 mg twice a day, with
initial titration up over week 1) and smoking cessation coun-
seling targeted to the issues of thoracic cancer patients. We had
proposed to offer seven counseling sessions but were flexible in
offering additional sessions when needed. The counseling was
delivered by a certified Tobacco Treatment Counselor using
motivational interviewing techniques.23 Motivational interview-
ing is a counseling style that seeks to enhance individuals’
readiness to change behavior by emphasizing a smoker’s choice,
personal responsibility, and self-efficacy.
The initial counseling session took place during the base-
line visit or by telephone within 48 hours of study enrollment
and focused on the cancer-specific benefits of quitting smoking,
forming a quit smoking plan, and instructions on study medica-
tion use and adherence. Follow-up counseling sessions were
conducted by telephone, or in person when possible, with stan-
dardized counseling modules. All sessions were structured ac-
cording to the five As brief counseling model (Ask, Advise,
Assess, Assist, Arrange follow-up) and included cancer-specific
and general smoking cessation and relapse prevention topics.22
Intervention content was selected based on the principal inves-
tigator’s previous work,24,25 published smoking cessation work
with cancer patients, and lessons learned about the population
during the control group observation period (e.g., high levels of
environmental tobacco smoke). We targeted modifiable factors
that previous research has shown associated with cancer pa-
tients’ quitting and staying quit: emotional distress (lower anx-
iety and depression scores) and smoking and cancer beliefs
(higher perceived risk of cancer recurrence, higher self-efficacy
to quit, and higher quit motivation).5,17,18,20,26–33
Measures
Sociodemographics
At baseline, age, gender, race/ethnicity, education, mar-
ital status, and employment were assessed with a question-
naire and medical record review.
Cancer and Medical History
Previous cancer history and family history of lung disease,
cancer, and heart disease were collected from the clinic screen-
ing form. Cancer status variables (diagnosis, stage, and treat-
ment modalities) were abstracted from the medical records.
Psychosocial Factors
Emotional support was measured at baseline and fol-
low-up using four items from the emotional/informational scale
of the Medical Outcomes Study social support survey, a reliable
scale (  0.96) that has been widely used with cancer pa-
tients.34–37 Smoking-specific support was measured at baseline
and follow-up using a single, Likert-type, response item. De-
pression and anxiety symptoms were measured at baseline and
follow-up via the Hospital Anxiety and Depression Scale,38 a
14-item assessment of mood with depression and anxiety sub-
scales that has been well tested in cancer patients.35,38–40 Par-
ticipants with scores 8 on the depression or anxiety subscales
were considered to have elevated levels of depressed mood or
anxiety. Participants rated current levels of pain and stress at
baseline and follow-up on a 0 to 10 scale.41
Smoking Characteristics
Smoking history (years smoked and past cessation
treatment) was assessed in the baseline questionnaire. Current
nicotine dependence was measured at baseline using the two
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items from the Fagerstro¨m Test for Nicotine Dependence
(FTND),42–44 which have been found to account for the bulk
of the predictive validity of the FTND: number of cigarettes
per day and time to first cigarette after waking. Smoking
environment (live with a smoker and home policy) was
assessed at baseline and follow-up. Participants were asked to
rate, on a 10-point scale, their attitudes about quitting smok-
ing (the importance of quitting smoking and confidence in
ability to quit) and knowledge about the benefits of quitting
smoking after a cancer diagnosis.
Feasibility
Feasibility was assessed by rates of study eligibility,
recruitment, retention, and intervention adherence (counsel-
ing and medication).
Smoking Outcome
Seven-day point prevalence abstinence (“Have you
smoked a cigarette, even a puff, in the past 7 days?”) was
assessed at 2- and 12-week follow-up points. Self-reported
abstinence was confirmed only if a salivary cotinine level was
less than 15 ng/ml or an expired carbon monoxide measure-
ment was less than 10 ppm. Some participants returned saliva
samples with insufficient quantity for cotinine assay. For the
primary analysis, participants who did not complete the
survey or return analyzable saliva samples were considered to
be smokers. A secondary analysis counted self-reported non-
smokers who returned saliva samples with insufficient quan-
tity for assay as nonsmokers.
Data Analysis
All data analyses were conducted using SPSS 18.0.
Using 2 tests and one-way analyses of variance, we com-
pared the sociodemographics and smoking histories of eligi-
ble participants who enrolled with those who declined to
enroll to determine whether study participants were similar to
the MGH thoracic patient population. A similar analysis
explored the comparability of the intervention and usual care
control groups. The primary outcome measure, biochemically
confirmed 7-day point prevalence tobacco abstinence as de-
fined above, was compared between groups using a univariate
logistic regression. Analyses examined variables associated
with 12-week smoking status with participants from both
treatment groups. Logistic regressions were conducted with
baseline characteristics of interest as the independent variable
and then with changes in intervention targets predicting
12-week smoking status.
RESULTS
Recruitment
We screened 1130 patients in the MGH thoracic sur-
gery and oncology clinics; 187 (17%) identified themselves
as smokers, and an additional 66 (6%) reported quitting
within the past 6 months (Figure 1). Of the current smokers
in whom eligibility could be assessed, 116 (67%) were
eligible, and 49 (42%) enrolled. The most common reason for
ineligibility was having metastatic cancer. The main reason
for declining participation was reluctance to take varenicline.
Other reasons for refusal included preferring to quit on one’s
own, having no interest in quitting, feeling overwhelmed, or
not having time to participate. Those who enrolled did not
differ from those who refused in terms of sociodemographic
characteristics, medical history, or past use of nicotine re-
placement therapy or bupropion (all p  0.05). However,
those who enrolled were significantly more likely to report
using or having used varenicline (34.8% versus 12.8%; p 
0.02) and marginally more likely to have used smoking
cessation counseling in the past (31.0% versus 14.8%; p 
0.06). Enrollees had higher rates of anxiety (55.9% versus
26.1%; p  0.007).
Participants
Tables 1 and 2 display the characteristics of the 49
participants; 59.2% were female, 87.8% were white, and the
mean age was 57.7 years. The intervention and control group
participants did not differ significantly in sociodemographic
factors, smoking history, or medical history. Most partici-
pants were long-term, highly dependent smokers with low
levels of confidence in their ability to quit. Only 31.0% had
ever used smoking cessation counseling, and 64.4% had ever
FIGURE 1. Study recruitment and retention. *Three con-
trol participants were removed due to ineligibility status
that emerged after recruitment (metastatic disease, non-
surgical status); subsequently, the decision was made to
retain patients, regardless of their postenrollment disease/
treatment status.
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used pharmacotherapy. Participants generally agreed that
quitting would reduce the risk of treatment complications and
the risk of future tumors.
Intervention Adherence
Participants in the intervention group completed a me-
dian of nine counseling sessions and had a median of 88
minutes of total counseling contact time. The average initial
contact was approximately 20 minutes, and the follow-up
sessions were approximately 10 minutes. Participants re-
ceived an average of six counseling sessions before initiating
cancer treatment, which started a mean of 51 (SD45.2) days
after study enrollment (Figure 2). Half of the participants who
took varenicline completed the full treatment course, and
23.3% took the medication for 4 to 8 weeks. The most
common side effect was nausea, reported by one-third of
participants; eight (26.7%) participants discontinued the med-
ication due to side effects (seven for abnormal dreams and/or
nausea and one for feelings of agitation/aggression).
Smoking Cessation Rates
Self-reported nonsmokers complied with 97% of re-
quests for saliva samples (Table 3). Using the conservative
method of considering participants with insufficient saliva
samples as smokers (Table 3, version 2), cotinine-confirmed
7-day point prevalence abstinence rates were 28.1% in the
intervention group versus 14.3% in the control group (odds
ratio [OR]  2.35, 95% confidence interval [CI]  0.44–
12.64, p  0.32) at 2-week follow-up and 34.4% in the
intervention group versus 14.3% in the control group (OR 
3.14, 95% CI 0.59–16.62, p 0.18) at 12-week follow-up.
In a secondary analysis that considered participants with
insufficient cotinine samples as nonsmokers (Table 3, version
1) cotinine-confirmed 7-day point prevalence abstinence rates
were 37.5% in the intervention group versus 28.6% in the
control group (OR  1.50, 95% CI  .38–5.86, p  0.56) at
2-week follow-up and 40.6% in the intervention group versus
14.3% in the control group (OR  4.11, 95% CI  0.79–
21.48, p  0.09) at 12-week follow-up.
Characteristics Associated with Cotinine-
Confirmed (Version 2) 12-Week Abstinence
Across Groups
Sociodemographic factors were not associated with
abstinence at 12 weeks. Participants with lower baseline
TABLE 1. Sociodemographic, Medical, and Psychosocial Characteristics of Participants
Variable All (N  49) Control (N  17) Intervention (N  32) p
Sociodemographics
Age, mean (SD) 57.7 (12.4) 58.0 (10.5) 57.5 (13.4) 0.90
Female (%) 59.2 52.9 62.5 0.56
White, non-Hispanic (%) 87.8 94.1 84.4 0.65
Education (%)
High school 12.2 5.9 15.6 0.65
High school/GED 36.7 35.3 37.5
High School 51.0 58.8 46.9
Marital status (%)
Married/living with a partner 49.0 52.9 46.9 0.69
Widowed/divorced/separated 32.7 35.3 31.3
Never married 18.4 11.8 21.9
Employed (%) 49.0 58.8 43.8 0.38
Medical history
Past history of cancer (%) 18.9 23.5 15.0 0.68
Thoracic cancer diagnosis (%) 66.0 58.8 70.0 0.53
Cancer treatment (%)
Surgery only 57.6 72.7 50.0 0.45
Chemotherapy  radiation 30.3 18.2 36.4
Surgery  chemotherapy/radiation 12.1 9.1 13.6
Psychosocial factors
Emotional support, mean (SD)a 3.5 (1.3) 3.8 (1.5) 3.4 (1.2) 0.26
Smoking-specific support, mean (SD)b 3.7 (0.67) 3.8 (0.4) 3.6 (0.8) 0.40
HADS Anxiety subscale 8 (%)d 63.3 52.9 68.8 0.34
HADS Depression subscale 8 (%)d 34.7 35.3 34.4 1.00
Stress rating, mean (SD)c 6.4 (3.1) 6.4 (3.2) 6.4 (3.0) 0.98
Pain rating, mean (SD)c 3.3 (3.3) 3.8 (3.6) 3.0 (3.1) 0.44
a Emotional support, 1–5 scale; 1  none of the time, 5  all of the time.
b Smoking-specific support, 1–4 scale; 1  none, 4  a lot.
c Pain and stress, 0–10 scale; 0  no pain/stress, 10  worst pain/stress imaginable. dHospital Anxiety and Depression Scale (HADS), 8 on the depression or anxiety
subscales  elevated levels of depressed mood or anxiety.
GED, General Equivalency Diploma.
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FIGURE 2. Timeline of smoking cessation coun-
seling sessions and cancer treatment initiation.
TABLE 2. Baseline Smoking Characteristics
Variable All (N  49) Control (N  17) Intervention (N  32) p
Smoking characteristics
Years smoked, mean (SD) 37.8 (13.9) 34.1 (13.7) 39.7 (13.8) 0.18
Cigarettes per day, mean (SD) 16.4 (11.6) 15.4 (9.0) 17.0 (12.8) 0.65
Smoke within 30 min of waking (%) 76.6 73.3 78.1 0.72
Past cessation treatment (%)
Any counseling 31.0 41.7 26.7 0.46
Any pharmacotherapy 64.4 73.3 60.0 0.38
Nicotine replacement therapy 44.4 50.0 41.9 0.75
Varenicline 34.8 43.8 30.0 0.52
Bupropion 25.0 33.3 21.4 0.45
Live with a smoker (%) 34.7 35.3 34.4 0.95
Allows smoking in home (%) 87.8 94.1 84.4 0.33
Importance of quitting, mean (SD)a 8.9 (2.5) 8.1 (3.1) 9.3 (2.0) 0.12
Confidence in ability to quit, mean (SD)b 5.9 (2.8) 5.4 (3.0) 6.3 (2.6) 0.28
Knowledge about smoking and cancer, mean (SD)c
Quitting will reduce treatment complications 8.9 (2.0) 8.6 (2.6) 9.0 (1.8) 0.56
Quitting will result in living longer 9.3 (1.5) 9.4 (1.4) 9.2 (1.5) 0.73
Quitting will reduce likelihood of future tumors 8.9 (2.0) 8.7 (1.9) 9.0 (2.1) 0.62
a Importance of quitting, 1–10 scale; 1  not at all, 10  very important.
b Confidence in ability to quit, 1–10 scale; 1  not at all, 10  very confident.
c Knowledge about smoking and cancer, 0–10 scale; 0  not at all, 10  very much.
TABLE 3. Smoking Outcomes
All (N  46) Intervention (N  32) Control (N  14) OR (95% CI)
7-d point prevalence tobacco abstinence
2 wk
Self-reported 17/46 (37.0%) 13/32 (40.6%) 4/14 (28.6%) 1.23 (0.34–4.52)
Cotinine-confirmed (version 1)a 16/46 (34.8%) 12/32 (37.5%) 4/14 (28.6%) 1.50 (0.38–5.86)
Cotinine-confirmed (version 2)b 11/46 (23.9%) 9/32 (28.1%) 2/14 (14.3%) 2.35 (0.44–12.64)
12 wk
Self-reported quit 17/46 (37.0%) 14/32 (43.8%) 3/14 (21.4%) 2.85 (0.67–12.22)
Cotinine-confirmed (version 1)a 15/46 (32.6%) 13/32 (40.6%) 2/14 (14.3%) 4.11 (0.79–21.48)
Cotinine-confirmed (version 2)b 13/46 (28.3%) 11/32 (34.4%) 2/14 (14.3%) 3.14 (0.59–16.62)
a Analysis with insufficient returned saliva samples counted as nonsmokers.
b Analysis with insufficient returned saliva samples counted as smokers.
OR, odds ratio; CI, confidence interval.
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levels of depressive symptoms were more likely to be absti-
nent (OR  0.81, 95% CI  0.67–0.98, p  0.03). There
were trends associating 12-week abstinence with smoking
within 30 minutes of waking (OR 3.86, 95% CI  0.87–
17.16, p  0.08), believing that quitting smoking was impor-
tant (OR  1.28, 95% CI  0.94–1.75, p  0.11) and that
continued smoking caused surgical complications (OR 
1.56, 95% CI  0.87–2.79, p  0.14). Receiving a cancer
diagnosis by the end of the study period (OR  4.05, 95%
CI  0.77–21.26, p  0.10) and having surgery (OR  3.05,
95% CI  0.78–1.96, p  0.11) were marginally associated
with 12-week abstinence. Time to treatment was not associ-
ated with 12-week abstinence (OR  0.99, 95% CI 
0.98–1.01, p  0.48). An increase in quit confidence from
baseline to follow-up was associated with 12-week absti-
nence (OR  1.74, 95% CI  1.06–2.88, p  0.03).
DISCUSSION
The current study is, to our knowledge, the first con-
trolled study of a combined behavioral and pharmacological
tobacco treatment program targeting patients at their entry
into thoracic surgery and thoracic oncology clinics. We found
that the program was feasible and acceptable. Furthermore,
the intervention produced higher biochemically validated
smoking cessation rates at the end of treatment, although the
difference did not reach statistical significance due to the
small sample size of this pilot study.
Our findings show that those who continue smoking
after a lung cancer diagnosis are a challenging population
with a long smoking history, high nicotine dependence, and
low confidence to quit. This indicates that this particular
population of smokers likely needs intensive tobacco treat-
ment, preferably one that combines pharmacological support
with extended counseling to achieve abstinence.
We were able to enroll almost half of the eligible
patients at their entry into the thoracic oncology setting, a rate
similar to previous smoking cessation studies that enrolled
patients after cancer treatment.33 Enrolling as early as possi-
ble is critical because the closer to the time of diagnosis that
smoking cessation treatment is delivered, the greater the
health benefits, including reduced perioperative morbidity,
and the higher the likelihood for continued absti-
nence.2,4,5,32,45 The main reasons for refusal, reluctance to
take varenicline and wanting to quit unassisted, could repre-
sent quitting preferences, but these could also be proxies for
not wanting to quit. Another factor to consider is that during
the study enrollment period, varenicline received a black box
warning about psychiatric side effects, which may have
caused some reluctance in smokers.46
We were able to engage patients in tobacco treatment
during a vulnerable and critical period. The program length
matched the USPHS recommended 90 minutes of contact
time, but the number of contacts exceeded the USPHS min-
imum recommended number of sessions, which are usually
offered for telephone-delivered smoking cessation interven-
tions.22,24,47 These patients seemed to need frequent, brief
contacts and social support to promote tobacco abstinence.
Despite initial concerns that cancer patients might not
tolerate varenicline due to side effects similar to cancer
treatment side effects (e.g., nausea), participant adherence
rates to varenicline were similar to nicotine replacement
therapy (NRT) use in cancer patients and noncancer pa-
tients.48,49 Similar to varenicline in the general population,
nausea was the most common side effect that is reported in
one-third of the participants.
This study had several limitations. The generalizabil-
ity of the findings was limited by using only a single study
site. The statistical power to detect differences was limited
by the small sample size of this pilot study. Although the
sample size cannot be increased in accordance to power
calculations that would enable detection of a statistically
significant difference, we believe that the encouraging
nonstatistical trend provides a rationale for an adequately
powered RCT. Its nonrandomized design leaves open the
potential for unmeasured confounding due to group dis-
similarities.
Despite these limitations, our combined behavioral and
varenicline intervention produced promising feasibility and
potential efficacy results. In pursuit of a larger scale random-
ized trial to assess the efficacy of our counseling plus vareni-
cline treatment, we recommend comparison of two treatment
arms: an “intensive” counseling plus varenicline versus a
“brief” counseling plus varenicline. A counseling only or
varenicline only comparison group would not be in compli-
ance with clinical practice guidelines. In addition, a counsel-
ing only comparison would not build on this work, which
supported the tolerability of varenicline in this population,
and given the psychological and medical vulnerability of this
population, it is not preferable to use a varenicline only
comparison.
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